Get started
Award

110515

Funded outputs count: 18
Funder award ID: 110515
OpenAlex ID: G5882935763
A machine learning–derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL
2026 · Fabian Ullrich, René Hosch, et al. · Blood Advances
Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response
2025 · Jakoba J. Eertink, Martijn W. Heymans, et al. · Haematologica · 2
PDF
Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial
2025 · Ulrich Dührsen, Gabriele Prange-Krex, et al. · Annals of Hematology
PDF
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial
2024 · Ulrich Dührsen, Andreas Bockisch, et al. · Blood Neoplasia · 5
Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
2023 · Jakoba Johanna Eertink, Gerben JC Zwezerijnen, et al. · Blood · 38
PDF
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
2022 · Jakoba J. Eertink, Gerben J. C. Zwezerijnen, et al. · Blood Advances · 20
PDF
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial
2022 · Robert Seifert, David Kersting, et al. · Leukemia · 7
PDF
Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma
2021 · MJE Greuter, JJ Eertink, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
PDF
Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial
2021 · Martina Broecker-Preuss, Nina Becher-Boveleth, et al. · Journal of Cancer Research and Clinical Oncology · 5
PDF
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
2021 · Dominic Kaddu-Mulindwa, Bettina Altmann, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 40
PDF
FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Patients With Aggressive Non-Hodgkin Lymphoma: Results From the Prospective, Multicenter PETAL and OPTIMAL>60 Trials
2021 · Dominic Kaddu-Mulindwa, Bettina Altmann, et al. · Research Square
PDF
Genetic Variants of the NKG2C/HLA-E Receptor–Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma
2020 · Bettina Wagner, Ulrich Dührsen, et al. · Cancers · 10
PDF
Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy
2020 · Christine Schmitz, Jan Rekowski, et al. · Cancer Medicine · 12
PDF
Baseline and interim PET‐based outcome prediction in peripheral T‐cell lymphoma: A subgroup analysis of the PETAL trial
2020 · Christine Schmitz, Jan Rekowski, et al. · Hematological Oncology · 27
PDF
Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination
2019 · Christine Schmitz, Andreas Hüttmann, et al. · Data in Brief · 3
PDF
Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial
2019 · Christine Schmitz, Andreas Hüttmann, et al. · European Journal of Cancer · 99
Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome
2019 · Julia Richter, Andreas Hüttmann, et al. · Blood Cancer Journal · 17
PDF
Year
Topic